‘Breakthrough Therapy’ Designations
Listing of all ‘breakthrough’ drugs, including status and basis of designation. Updated weekly.
You may also be interested in...
After a record-setting 2015 for new drug approvals, there were not enough applications with user fee goals in 2016 to reach that level again.
User fees won't support dedicated staff, but rather FTEs that will work on the popular program as needed.
Biosimilars could be affected significantly by Build Back Better’s drug price negotiations provision, but industry associations and analysts differ on just how much.